Novo Nordisk Joins Biopharma Companies Challenging Drug Price Negotiations in Inflation Reduction Act

Novo Nordisk and numerous other biopharma companies are challenging drug price negotiation provisions in the Inflation Reduction Act. Novo has filed a lawsuit claiming the act violates their First and Fifth Amendment rights. Despite their resistance, Novo and other companies have agreed to participate in the negotiation process and meet the October 1 deadline set by the Centers for Medicare & Medicaid Services (CMS). Furthermore, Novo contends that the CMS has deemed six of its insulin treatments as a singular product for price control despite the drugs having distinct formulations and separate FDA approvals. Companies such as AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Johnson & Johnson, Novartis, and Merck have also filed lawsuits.

To read more, click here.